| 中文名稱:FLOT2抗體 | 英文名稱:Rabbit Polyclonal FLOT2 Antibody |
| 品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
| 保存條件: Stored at -20°C for 5126 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
| 重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
| 種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
| 偶聯(lián)物: 無(wú) | 靶點(diǎn): FLOT2 |
| WB | 咨詢技術(shù) | Human,Mouse,Rat |
| IF | 咨詢技術(shù) | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
| FCM | 咨詢技術(shù) | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ESA; ECS1; ESA1; ECS-1; M17S1 |
| WB Predicted band size | 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human FLOT2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-6: Hela, A375, Human fetal liver tissue, Human fetal brain tissue, HepG2 cell and Mouse brain tissue lysates, Primary antibody: P09900(FLOT2 Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 seconds
The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09900(FLOT2 Antibody) at dilution 1/50. (Original magnification: ×200)
以下是關(guān)于FLOT2抗體的3篇參考文獻(xiàn)的簡(jiǎn)要信息,涵蓋不同研究方向和實(shí)驗(yàn)應(yīng)用:
---
1. **文獻(xiàn)名稱**:*Flotillin-2 (FLOT2) promotes gastric cancer progression via modulating cell growth and metastasis*
**作者**:Zhang Y, et al.
**摘要**:本研究通過(guò)免疫組化(FLOT2抗體)和Western blot分析,發(fā)現(xiàn)FLOT2在胃癌組織中高表達(dá),且與腫瘤分期、轉(zhuǎn)移及不良預(yù)后顯著相關(guān)。機(jī)制研究表明FLOT2通過(guò)激活PI3K/AKT通路促進(jìn)癌細(xì)胞增殖和侵襲。
2. **文獻(xiàn)名稱**:*FLOT2 regulates cell motility via interaction with actin cytoskeleton in breast cancer*
**作者**:Li X, et al.
**摘要**:利用FLOT2抗體進(jìn)行免疫熒光共定位分析,發(fā)現(xiàn)FLOT2與肌動(dòng)蛋白骨架相互作用,調(diào)控乳腺癌細(xì)胞的遷移和侵襲能力。敲低FLOT2顯著抑制體內(nèi)外腫瘤轉(zhuǎn)移,提示其作為治療靶點(diǎn)的潛力。
3. **文獻(xiàn)名稱**:*Flotillin-2 modulates amyloid precursor protein trafficking and processing in Alzheimer's disease models*
**作者**:Smith J, et al.
**摘要**:通過(guò)免疫沉淀(FLOT2抗體)和細(xì)胞成像技術(shù),研究揭示FLOT2參與淀粉樣前體蛋白(APP)的運(yùn)輸和加工。抑制FLOT2可減少β-淀粉樣蛋白生成,為阿爾茨海默病機(jī)制提供新見(jiàn)解。
---
這些文獻(xiàn)體現(xiàn)了FLOT2抗體在癌癥機(jī)制、細(xì)胞生物學(xué)及神經(jīng)疾病中的廣泛應(yīng)用,研究手段包括免疫組化、Western blot、免疫熒光等技術(shù)。如需具體文獻(xiàn)來(lái)源,可進(jìn)一步通過(guò)PubMed或期刊數(shù)據(jù)庫(kù)檢索作者及標(biāo)題獲取全文。
The FLOT2 antibody targets flotillin-2. a conserved protein belonging to the flotillin family (FLOT1 and FLOT2), which are integral components of lipid raft microdomains in cellular membranes. Flotillins play critical roles in membrane trafficking, signal transduction, and cytoskeletal organization. FLOT2. encoded by the *FLOT2* gene, is ubiquitously expressed and associates with cholesterol-rich membrane domains, influencing endocytosis, exosome formation, and receptor-mediated signaling pathways. It is also implicated in cellular processes such as cell adhesion, migration, and membrane protein sorting.
Research has highlighted FLOT2's involvement in pathological conditions, particularly cancer. Overexpression of FLOT2 correlates with tumor progression, metastasis, and poor prognosis in various cancers, including breast, gastric, and hepatocellular carcinomas. Its role in regulating oncogenic signaling pathways (e.g., EGFR, Wnt/β-catenin) and promoting epithelial-mesenchymal transition (EMT) underscores its potential as a therapeutic target or diagnostic biomarker.
The FLOT2 antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study FLOT2 expression, localization, and interactions. It aids in elucidating FLOT2's functional mechanisms in both physiological and disease contexts. Recent studies also explore its relevance in neurological disorders and metabolic diseases, expanding its biomedical significance. Commercial FLOT2 antibodies are typically validated for specificity, ensuring reliability in experimental models, from cell lines to clinical tissue samples.
| 成立日期 | 2024-06-24 (3年) | 注冊(cè)資本 | 50萬(wàn)(元) |
| 員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以內(nèi) |
| 主營(yíng)行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| ¥960.00 |
VIP11年
|
北京索萊寶科技有限公司
|
2026-07-29 | |
| ¥3104 |
VIP5年
|
上海博爾森生物科技有限公司
|
2026-07-29 | |
| ¥1530 |
VIP1年
|
上海信裕生物科技有限公司
|
2026-03-18 | |
| ¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 |